Sino Biopharm Earnings: 2024 Revenue Is Just Shy of Estimate, but Guidance on Pipeline Lifts Outlook

No-moat Sino Biopharmaceutical’s 2024 results slightly missed our forecast and PitchBook consensus. However, management provided a more robust pipeline update in the earnings call, improving our view of its oncology segment in the long run. Hence, we lift our oncology segment revenue growth assumptions for 2025 and beyond. The upward revision in revenue forecasts offset a few adjustments we made following the 2024 earnings release. Consequently, our fair value estimate is nudged up to HKD 3.93 from HKD 3.88. We now view the shares as fairly valued after a more than 15% jump in the share price since the beginning of the year.